61
GALARZA JOSE: Universal virus-like particle (vlp) influenza vaccines. TECHNOVAX, Pasternak Dahna S, August 25, 2011: WO/2011/102900 (3 worldwide citation)

Described herein are influenza virus-like particles (VLPs) that display one or more truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.


62
Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe: Adjuvanted influenza vaccines including cytokine-inducing agents. Novartis Vaccines And Diagnostics, Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe, MARSHALL Cameron John, May 10, 2007: WO/2007/052056 (3 worldwide citation)

While oil-in-water emulsions are excellent adjuvants for influenza vaccines, their efficacy can be improved by additionally including other immunostimulating agent(s) to improve cytokine responses, such as ϝ-interferon response. Thus a vaccine comprises: (i) an influenza virus antigen; (ii) a ...


63
Scheffczik Hanno: Storage of influenza vaccines without refrigeration. Novartis Vaccines And Diagnostics & Co Kg, Scheffczik Hanno, MARSHALL Cameron John, October 4, 2007: WO/2007/110776 (3 worldwide citation)

Antigens from individual influenza virus strains are not refrigerated before being combined to make multivalent influenza virus vaccines. Moreover, influenza vaccines are not refrigerated between packaging and administration. Thus the need for refrigeration is minimized, and the cold-chain does not ...


64
Couture Manon, Landry Nathalie, Vezina Louis Philippe, Dargis Michèle: Soluble recombinant influenza antigens. Medicago, Couture Manon, Landry Nathalie, Vezina Louis Philippe, Dargis Michèle, Sechley Konrad A, January 14, 2010: WO/2010/003235 (3 worldwide citation)

The present invention provides a recombinant soluble trimeric hemagglutinin (rHA) protein comprising a hemagglutinin ectodomain and an oligomerization domain. The rHA is produced as a soluble homotrimer, and may further comprises a signal peptide and/or an endoplasmic reticulum (ER) retention signal ...


65
BAKER David, WHITEHEAD Timothy A, FLEISHMAN Sarel: Polypeptides pour traitement et/ou limitation dinfection par la grippe, Polypeptides for treating and/or limiting influenza infection. University Of Washington Through Its Center For Commercialization, BAKER David, WHITEHEAD Timothy A, FLEISHMAN Sarel, OSLICK Sherri L, February 9, 2012: WO/2012/018907 (3 worldwide citation)

The present invention provides polypeptides according to the general formulas disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection. The present invention further provides isolat ...


66
Erich Hoffmann, Hong Jin, Bin Lu, Gregory Duke, George Kemble, Zhongying Chen: Method for producing temperature sensitive influenza A viruses. Medimmune, Grant Anderson, February 14, 2012: US08114415 (2 worldwide citation)

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing ...


67
Erich Hoffman, Hong Jin, Bin Lu, Greg Duke, George Kemble: Multi plasmid system for the production of influenza virus. MedImmune, Grant IP, May 13, 2014: US08722059 (2 worldwide citation)

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.


68
Qi Dang, Richard Schwartz: Methods of producing influenza vaccine compositions. MedImmune, March 31, 2009: US07510719 (2 worldwide citation)

Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.


69
Erich Hoffmann, Aleksandr S Lipatov, Richard J Webby, Elena A Govorkova, Robert G Webster: Modified influenza virus for monitoring and improving vaccine efficiency. St Jude Children s Research Hospital, Fish & Richardson P C, January 18, 2011: US07871626 (2 worldwide citation)

The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by alt ...


70
Jules Maarten Minke, Kemal Karaca, Jiansheng Yao: Canine influenza vaccines. Mevial, Judy Jarecki Black, Mevial, Thomas Kowalski Esq, September 16, 2008: US07425336 (2 worldwide citation)

The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens w ...



Click the thumbnails below to visualize the patent trend.